About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer

NCT01423695·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

WiSP Wissenschaftlicher Service Pharma GmbH

With

Bristol-Myers Squibb
Roche Pharma AG

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

histologically confirmed metastatic breast cancer overexpressing HER2
pretreatment with anthracycline in either the adjuvant or palliative setting.
HER2 positivity was defined as 2+ or 3+ overexpression using the DAKO HercepTest, confirmed by fluorescence in-situ hybridization (FISH) if 2+.
informed consent

You may not be if

more than 1 chemotherapy for advanced disease
taxane or trastuzumab pretreatment
brain metastases
Eastern Cooperative Oncology Group (ECOG) performance status \>1
pregnancy or lactation, childbearing potential without reliable contraception
clinically significant cardiac disease,
neutrophils \<1500/µl, platelets \<75,000/µl
total bilirubin and creatinine \>1.5 × the upper limit of normal

The record

StatusCompleted

PhasePhase 2

Taking part121

StartedFeb 2001

UpdatedAug 26, 2011

Conditions

Metastatic Breast Cancer

Where1

Dr. Matthias John
Glauchau, Saxony, Germany

Clareo Health | Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer